CN105410937A - Production process of beatifying calcium dispersible tablet - Google Patents
Production process of beatifying calcium dispersible tablet Download PDFInfo
- Publication number
- CN105410937A CN105410937A CN201510347932.8A CN201510347932A CN105410937A CN 105410937 A CN105410937 A CN 105410937A CN 201510347932 A CN201510347932 A CN 201510347932A CN 105410937 A CN105410937 A CN 105410937A
- Authority
- CN
- China
- Prior art keywords
- raw material
- calcium
- mesh sieve
- donkey
- hide gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 44
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 44
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 239000007919 dispersible tablet Substances 0.000 title abstract 2
- 108010010803 Gelatin Proteins 0.000 claims abstract description 45
- 239000008273 gelatin Substances 0.000 claims abstract description 45
- 229920000159 gelatin Polymers 0.000 claims abstract description 45
- 235000019322 gelatine Nutrition 0.000 claims abstract description 45
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 45
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims description 34
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 16
- 235000020985 whole grains Nutrition 0.000 claims description 15
- 238000007873 sieving Methods 0.000 claims description 14
- 241000257303 Hymenoptera Species 0.000 claims description 13
- 230000003796 beauty Effects 0.000 claims description 12
- 239000003595 mist Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 9
- 235000010216 calcium carbonate Nutrition 0.000 claims description 6
- 239000011122 softwood Substances 0.000 claims description 6
- -1 500 parts Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000021050 feed intake Nutrition 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000011265 semifinished product Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000013081 microcrystal Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 244000068988 Glycine max Species 0.000 abstract description 4
- 235000010469 Glycine max Nutrition 0.000 abstract description 4
- 238000000227 grinding Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 2
- 238000004513 sizing Methods 0.000 abstract 2
- 239000003826 tablet Substances 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 abstract 1
- 238000011020 pilot scale process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 37
- 208000007502 anemia Diseases 0.000 description 22
- 238000011160 research Methods 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 230000036039 immunity Effects 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 206010006956 Calcium deficiency Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 235000006539 genistein Nutrition 0.000 description 5
- 229940045109 genistein Drugs 0.000 description 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 206010022971 Iron Deficiencies Diseases 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000009940 knitting Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000276489 Merlangius merlangus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 229940092124 calcium citrate malate Drugs 0.000 description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 241001251068 Formica fusca Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a product formula and a production process of the production technology comprising the steps of micro-powdering, crushing, granulating, drying, sizing, final blending and tablet compressing; and the invention belongs to the technical field of healthcare. The final process route is defined as follows: firstly, performing micro-powder treatment on donkey-hide gelatin; crushing calcium carbonate, soybean isoflavone and ant extract and then performing mesh-screening; performing mesh-screening on microcrystalline cellulose; blending according to the formula ratio; granulating by ethanol of certain concentration; sizing after drying; then performing final blending and tablet compressing, so that the beatifying calcium dispersible tablets which can be conveniently taken are produced. Inspections prove that all the pilot-scale products meet the requirements of the quality standard; thus, the process is verified as stable, rational, feasible and suitable for industrial production.
Description
Technical field
The present invention relates to beauty treatment to replenish the calcium the production technology of the formula for a product of dispersing tablet and production technology pulverizing, granulation, drying, whole grain, total mixed, compressing tablet, belong to health product technology field.
Background technology
anaemia, anaemia refers to that human peripheral blood erythrocyte volume a surname is few, lower than a kind of common clinical symptoms of normal range (NR) lower limit.Because red blood cell volume measures more complicated, often clinically to replace with hemoglobin (Hb) concentration.China hematologist thinks that adult male Hb<120g/L, adult female's (non-pregnant) Hb<110g/L, pregnant woman Hb<100g/L just has anaemia in area, China sea level.
A major reason with hematopoiesis insufficient raw material or Use barriers Anemia in anaemia.Hematopoiesis raw material refers to hematopoietic cell proliferation, differentiation, the necessary material of metabolism, as protein, lipid, vitamin (folic acid, vitamin B12 etc.), trace element (iron, copper, zinc etc.) etc.Any one hematopoiesis insufficient raw material or Use barriers all may cause RBC acceptor garland rate to reduce.
1 folic acid or vitamin B12 deficiency or Use barriers Anemia cause the megaloblastic anemia that body folic acid or vitamin B12 definitely or relatively lack or Use barriers can cause due to various physiology or pathological factor.
2 iron deficiencies and iron Use barriers anaemia this be modal anaemia clinically.Iron deficiency and iron Use barriers affect ferroheme synthesis, have and claim such anaemia to be ferroheme resulting anomaly anaemia.The red cell morphology of such anaemia diminishes, and central olistherozone expands, and belongs to microcytic hypochromic anemia.
calcium, be the abundantest mineral matter element of people's in-vivo content, about 1.5% ∽ 2.0% of percentage of liveweight, always weigh 1200 ∽ 1300g, and wherein 99% is present in bone and tooth, forms human body support, and as the calcium warehouse of body; Remaining is distributed in blood, extracellular fluid and soft tissue cells, is referred to as miscible calcium pool, maintains dynamic equilibrium with bone calcium.Substantially the life process that body is all needs the participation of calcium, and calcium metabolic balance sustains life and healthy key factor.China's nutrition survey shows, national calcium intake is generally on the low side, is about 400 ∽ 500mg every day, only reaches about 50% of recommended amounts.Calcium deficiency can cause various diseases, should rationally replenish the calcium, to maintain the health status of health.
The physiological function of calcium:
The main component of 1 formation bone and tooth: Ca2+ and PO43-, CO32-and C2O42-etc. form the process of biogenic mineral biological calcification (BiologicalCalcification), and this important inorganic polymer composite flocculant is related to the formation of the sclerous tissues such as bone and tooth.
The activity of 2 participation N&Ms: calcium is as the coupling factor between nervous excitation and contraction of muscle, all the time control the starting of contraction of muscle and the termination of diastole, when Ca2+ concentration in body fluid reduces, the excitability of N&M increases, there is Spontaneous Contraction in muscle, has a convulsion time serious; When Ca2+ concentration in body fluid increases, then suppress the excitement of N&M.
3 participate in coagulation process: blood clotting is by a series of clotting factor, the mutual synergistic process of fibrin, this process relates to multiple enzyme, the proenzyme of some of them non-activity must be activated into activated enzyme and just can play hemoglutination, the activation of Ca2+ to enzyme plays a crucial role, under Ca2+ participates in, thrombokinase can change activated fibrin ferment into by catalyze prothrombin, make conversion of fibrinogen become insoluble fibrin, thus cause blood coagulation.
4 other physiological actions: calcium also participates in other physiological activities of human body, as there is activation to multiple enzyme, except above-mentioned fibrin ferment, also can activate adenosinetriphosphataes, adenyl cyclase, tyrosine hydroxylase, lipase, proteolytic enzyme, amylase, PDE etc.; Maintain colloidal stability in body fluid acid-base balance and cell; Control metabolism, hormone secretion, cell adhesion and division; Calcium bile acid and aliphatic acid in enteron aisle are combined and generate calcium soap, can relax enteron aisle spread effect, prevent colon cancer etc.
immunity, being the defense mechanism of human body self, is human bioequivalence and any foreign matter (virus, bacterium etc.) eliminating external intrusion; Process is old and feeble, damage, the ability of mutant cell and virus infected cell in the own cells of dead, sex change and identification and handling body.Immunology Today is thought, immunity is the physiological reaction of human bioequivalence and eliminating " dissident ".
Various microorganism is filled with: bacterium, virus, mycoplasma, Chlamydia, fungi etc. in air.In the hypodynamic situation of human immunity, they can become the pathogen of class as early as possible.Although human body can produce corresponding antibody to different pathogen, to resist subinfection again.But antibody has selectivity and time-bounded, such as streptococcus antibody compared with protecting body again not invade by streptococcic in short-term, also can only can not resist the infection of other viruses.
Modern medicine scientific discovery, immunity is one has the factor of substantial connection with aging, and immunocyte decline is one of most important reason of aging.Some special cells of body immune system can by the bacterium in invasion body, virus and body aging death cell, the cell suddenlyd change and cause allergic material, engulfed and eliminated, maintaining the stable of environment, keep body health.But body's immunity just started at about 30 years old to subtract late, and this change quietly, slowly, constantly carries out.
The health of hypoimmunity is easy to infected or cancer stricken; Immunity is extraordinary also can produce insalubrious result.The element improving immunity have trace elements of selenium, zinc, copper, magnesium, calcium, iron and folic acid, vitamin B6, B12 etc. with supporting one's family.
In China, since reform and opening-up, along with the concern deeply with to self health status improving constantly, be familiar with inferior health of people's living standard, health care consciousness promotes gradually, initiatively strengthen oneself quality of life, therefore people require to enrich blood, replenish the calcium, develop immunitypty, prevent and treat osteoporosis etc.There is increasing people can be higher a little on the low side or under normal circumstances at health indices, select to take health food, to reach the object of adjustment physical condition.
donkey-hide gelatin: the dry skin that donkey-hide gelatin (AsiniCoriiColla) is equine species donkey (Equusasi-nusL.) or fresh hide are through decocting, concentrating the solid gum made, with ginseng, pilose antler being called " nourishing Triratna ", begin to be loaded in Shennong's Herbal, be classified as top grade, Tao Hongjing is said: " going out Donga, therefore named donkey-hide gelatin ".Donkey-hide gelatin taste is sweet, property is put down, and returns lung, liver, kidney channel.There is enriching yin of enriching blood, moisturize, effect of hemostasis, be respectfully called enrich blood " panacea " by ancient Chinese medicine doctor.Cure mainly the deficiency of blood sallow, dizzy palpitaition, flesh impotence is unable, dysphoria and insomnia, endogenous deficient wind, xeropulmonary cough, and consumptive disease coughs spitting of blood, haematemesis hematuria, uterine bleeding of having blood in stool, vaginal bleeding during pregnancy.
The main gelatin containing ossein partial hydrolysis, protein and amino acid etc. in donkey-hide gelatin.Nitrogenous 16.43-16.54% is according to the literature the several amino acids that protein and hydrolysis produce substantially.Modern pharmacological research shows:
The research of 1 pair of hematological system effect: donkey-hide gelatin contains 18 seed amino acids, the wherein amino acid of 8 kinds of needed by human.Research shows, glycine by regulating serum levels of iron ion, can promote the synthesis of hemoglobin; Arginine impels body secretes auxin and stosterone, promotes the synthesis of hemoglobin; Threonine, histidine, lysine all have hematosis.
1.1 anti-anemia action effects: containing 20 various trace elements in donkey-hide gelatin, wherein abundant ferro element can be enriched blood, and a large amount of animal proteins very easily absorbs iron, helps the absorption of ferro element, thus effectively can treat hypoferric anemia.The results of study such as Song Yimin show the erythrocyte number of each dosage group mouse and content of hemoglobin all rise in various degree, show that donkey-hide gelatin effervescent particle has obvious blood tonification effect to phenylhydrazine hydrochloride type anemia mice, and certain dose-effect relationship may be there is.The research such as Wu Hongzhong illustrates that the donkey-hide gelatin component A, the B that are separated from the digestive system of in-vitro simulated people's stomach, intestines can hematopoietic stimulations; this active component of effectively enriching blood raise red, leukocytic mechanism of action may with protection anemia mice hematopoieticmicroenviron-ment and Hematopoietic Stem, CFU-GM, stimulate marrow hematopoietic cytokine of being correlated with to express relevant.
Research such as the protective effect of 1.2 pairs of hemopoietic systems: Deng Wanli etc. shows that donkey-hide gelatin active component can protect marrow stromal cell effectively, alleviates the damage of endoxan to myeloid tissue, protection hematopoietic tissue.The research such as Wu Hongzhong shows that can be separated donkey-hide gelatin from the digestive system of in-vitro simulated people's stomach, intestines effectively enriches blood active component, the mechanism of this composition protection irradiated mice hemopoietic system may with protection anemia mice hematopoieticmicroenviron-ment, stimulates body to express to be correlated with hematopoietic cytokine and to strengthen body antiradical activities relevant.Su Xiaomei etc. find that the bone marrow suppression of donkey-hide gelatin to animal model has obvious therapeutic action, and there is proportional relation between dosage and curative effect; To animal, there is nutritional support effect, show that the bone marrow suppression of donkey-hide gelatin to caused by chemotherapeutic medicines has certain therapeutic action.
1.3 anastalsis research: Wu Changhong etc. propose the anastalsis of donkey-hide gelatin may be relevant with the dermatan sulfate contained by it, and this is that the research of donkey-hide gelatin hemostasia effect provides research direction.
1.4 leukogenic effect researchs: the research such as Zheng Xiaoxiang shows that the Neuroleptic Leukocytopenia of donkey-hide gelatin to caused by cyclophosphamide has obvious therapeutic action.
The research of 2 pairs of enhancing immunity of organisms: the researchs such as a Xun show that donkey-hide gelatin has remarkable regulating action to mouse specificity and nonspecific mental retardation.Song Yimin etc. have studied the impact of donkey-hide gelatin effervescent particle on immune function of mice, show that donkey-hide gelatin effervescent particle can strengthen nospecific immunity and the cellular immune function of mouse.Lu Chengbiao etc. have studied the impact of Chinese medicine donkey-hide gelatin on mouse cell immunologic function, and result shows that donkey-hide gelatin can improve the special rose rate of body and Function of mononuclear phagocyte, can resist the Cellular immunity suppression effect caused by hydrocortisone, have facilitation to NK cell.
3 researchs on antitumor action: Liu Peimin etc. observe the impact of donkey-hide gelatin Contained Serum on K562 cell P53 gene expression.Show that the mechanism of donkey-hide gelatin to K562 cell induction apoptosis may be the expression by lowering P53, inducing cell stops division and proceeds to apoptosis and obtain result for the treatment of.
4 pairs promote the research of knitting effect: the research such as high cloud shows, mid-term early stage in knitting, donkey-hide gelatin can be strengthened Megakaryocytic gathering and strengthen its activity, and cartilage cell, osteoblastic propagation and synthesizing activity can be promoted, accelerate endochondral ossification, promote knitting, and to vascularization without obvious effect.The observation donkey-hide gelatin Contained Serums such as Changde has are on the impact of rat osteoblast in vitro propagation, differentiation function.Show that the propagation of donkey-hide gelatin to rat osteoblast in vitro is without facilitation, but the differentiation function of rat osteoblast in vitro can be promoted.
Dog experiment proves, on the basis giving basic feed, adding donkey-hide gelatin 30g/h with not adding to organize contrasts, and result shows that in food, the absorptivity of calcium obviously increases.Calcium balance in body can be improved, increase absorption and the retention in vivo of calcium.Just there is good blood tonification effect, and calcium balance in body can be improved, increase the absorption of calcium.
The research of 5 pairs of antifatigue effects: Li Hui etc. test and find that donkey-hide gelatin is rich in collagen, drug effect amino acid and essential amino acid isoreactivity composition, the energy significant prolongation mice burden swimming time, improve content of hemoglobin, the generation of serum urea nitrogen in the rear Mice Body of minimizing motion, significantly improves the deposit of Mouse Liver glycogen and reduces the generation of the rear blood lactase acid of motion.Show that donkey-hide gelatin has and alleviate mouse physical fatigue, improve the effect of exercise tolerance.
Supplementation product market demand is comparatively large, and listing kind is more, based on tablet and oral liquid.Oral liquid cost is high, carry inconvenience, good absorbing.Tablet price is lower, is calcium source mainly with calcium carbonate, calcium citrate, calcium citrate malate, absorbs better, easy to carry, taking convenience.But calcium citrate and calcium citrate malate content low, dose is large.
calcium carbonate: be the one that in medicinal calcium salt, content is the highest.Though water insoluble, be dissolved in hydrochloric acid in gastric juice, have good absorptivity, record into " Chinese Pharmacopoeia ".Its low price, taking convenience, has now become maximum, the most widely used calcium supplementing product of formulation.Production technology mainly contains two kinds, namely after the powdered whiting produced of natural whiting ore grinding and calcining through the precipitated calcium carbonate of digestion, carbonization, filtration, dry production.
isoflavones: (soybeanisoflavones, SiF) is Polyphenols mixture, and the composition of isoflavones, existence form mainly comprise genistein (Genistein, genistein), Daidezin (daidzein) and Glycitein (gly-citeln).Under its natural environment, they exist mainly with B-glucoside form greatly.Wherein play the mainly genistein of physiological function, Daidezin and glycosides thereof.Modern pharmacological research shows:
1 antitumor action: isoflavones has obvious antitumor action, particularly relevant to hormone tumour, as breast cancer and prostate cancer.In the prostatic cell proliferation stage, soybean protein has inhibitory action to it, thus can reduce the generation of tumor of prostate.
2 Cardiovasculars: Arroll reported first soybean protein can reduce cholesterolemia.Present research finds that the composition wherein played a major role is isoflavones.Mary result of study confirms the effect for reducing blood fat of isoflavones, T-CHOL, low-density lipoprotein (LDL), VLDL (VLDL), apolipoprotein B (ApoB) significantly decline, and the anti arteriosclerosis compositions such as HDL (HDL), aPoA (ApoA) significantly improve.
3 estrogen-like actions and to menopausal syndrome effect: soybean research mainly concentrates on the effect of isoflavones as phytoestrogen at present.Due to Long-Time Service hormone, the incidence of the cancer of the uterus is improved, therefore finds alternative medicine.Puberty, women ate the soybean protein containing isoflavones, and ovarian follicle extends mutually, and the menstrual cycle postpones, and corpus luteum shortens mutually.
4 antiinflammatory actions: the Chinese document before several thousand just describes soybean the effect controlling enteritis.Modern study shows that this effect is main relevant with genistein.
5 anti-osteoporosis disease effect: SIF can be used for the osteoporosis for the treatment of postmenopausal women.Be generally in osteocyte and osteoclast and all there is Estrogen receptor-β, when body inner estrogen quantity not sufficient, the regulating action of estrogen to female bone metabolic balance is lost thereupon, thus causes Progressive symmetric erythrokeratodermia bone loss, bone density is reduced, causes osteoporosis.SIF can stop the secretion of osteoclastic acid, reduces sclerotin and disappears molten.
6 anti-morning senile dementia effect: early senile dementia (Ah thatch's Alzheimer disease) is current modal a kind of dementia, take postmenopausal women as many trouble.Medical research shows that the effect of cholinergic nerve in human cognitive and Memory Process is extremely important, and activity and the cholinergic nerve of this disease and cholinacetyltranslase (chAT) reduce closely related.This type of patient treats with SIF, obviously can reduce the incidence of disease of this disease, relief of symptoms, recovers cognitive.
ant: the medical, edible of ant has long history in China, at present especially to be subject to people's attention.The ant whole world about has 260 genus, more than 7600 to plant, and China estimates at more than 600 kinds.The kind that studies have reported that is, black thorniness ant, tree ant, formica fusca L, the frightened ant of red mountain ant Huang etc.Ant nourishing composition enriches, it is reported, its protein content reaches 51.23%, free amino acid 27 kinds, wherein comprise all 8 kinds of necessary amino acid, trace element is abundant, has Mn, Zn, Se, Mg, Fe, Ca etc. 28 kinds to be rare high zinc food with the content of Zn far above soybean and other meat especially, also containing multivitamin, triterpene compound, multiple alkaloid, aldehyde compound.
Ant has dual regulation to immunologic function.It is reported, the formation of Promote immunity globulin and lymphocytic conversion, ant preparation also can improve low immunologic function significantly.In addition, ant, again by immunological regulation, is assisted the balance of T cell and suppressor T cell, plays immunodepressant, be used for the treatment of the rheumatism that the immunologic functions such as rheumatoid arthritis are hyperfunction.
The effect that ant is prolonged life to being healthy and strong.Ant comes in play the effect of being healthy and strong and prolonging life by multiple way.It is reported, ant liquid has obvious antifatigue, the effect of low temperature resistant, high temperature resistant, resist oxygen lack; Ant tool is significantly improved the activity of erythrocyte sod, reduces the effect of Serum LPO Levels and myocardial freedom base level, and has with drug matching the effect superposed; Ant powder can extend average life span, the maximum life span of fruit bat and ability of circling in the air significantly; Ant preparation also has identical effect.Therefore there is food ant can the saying of body-building among the people.
The present inventor is through repeatedly studying, and pass through many experiments, reasonable compatibility is carried out to above four kinds of raw materials, successfully make beauty treatment to replenish the calcium dispersing tablet, give full play to the physiological action of often kind of raw material, this product has replenishes the calcium, enriches blood, mends iron, beautifying function, up to now, does not also find the report of any technique similar with the present invention.
Summary of the invention
In order to postmenopausal women calcium deficiency, anaemia (enrich blood, mend iron), beauty treatment, the invention provides a kind of beauty treatment to replenish the calcium dispersing tablet, it is the sub-health population for postmenopausal women calcium deficiency, anaemia (enrich blood, iron deficiency), reasonable compatibility is carried out to donkey-hide gelatin, calcium carbonate, isoflavones, extract from ants, develop a kind of functional health-care food, the improvement of this product to postmenopausal women calcium deficiency, anaemia (enrich blood, iron deficiency) people's constitution will be played actively and advantageous effect.
The technical solution used in the present invention is to achieve these goals: a kind of beauty treatment is replenished the calcium dispersing tablet, and its main component weight portion is: 500 parts, donkey-hide gelatin, 500 parts, calcium carbonate, isoflavones 250 parts, extract from ants 130 parts, microcrystalline cellulose 75 parts, PVPP 30 parts, dolomol 15 parts and appropriate amount of ethanol.The present invention adopts the ethanol of debita spissitudo as adhesive, then dries, whole grain, adds magnesium stearate lubricant mixing, compressing tablet.The shaping of particle can be ensured, also can ensure the stability of product.
The replenish the calcium production technology of dispersing tablet of described beauty treatment is by carrying out micronizing to donkey-hide gelatin, calcium carbonate, isoflavones and extract from ants are pulverized, microcrystalline cellulose sieves, by donkey-hide gelatin, calcium carbonate, isoflavones, extract from ants, microcrystalline cellulose, mix by formula rate, use certain density alcohol granulation, whole grain after drying, always mix into PVPP and dolomol, be pressed into a point tablet, the beauty treatment of making taking convenience is replenished the calcium dispersing tablet, specifically carry out as follows: (1) is pulverized and sieved, donkey-hide gelatin first carries out micro mist process, then calcium carbonate, isoflavones and extract from ants are pulverized, and cross 60-120 mesh sieve, raw material for standby after sieving, (2) microcrystal cellulose powder crosses 60-120 mesh sieve, raw material for standby after sieving, (3) feed intake, calculate the actual inventory of each raw material by formula ratio, (4) mixing and wet granular processed: by having taken each raw material mixing 10-50 minute, making to mix, having added ethanol (40-90%) softwood processed in right amount, crosses 12-30 mesh sieve wet granular, (5) dry, obtained wet granular in an oven, 40 DEG C of-60 DEG C of dry 3-5 hour, (6) whole grain is with total mixed, and the whole grain of 12-30 mesh sieve excessively, adds PVPP and dolomol mixes, and obtains dry particle, (7) compressing tablet: after semi-finished product detect, by particle tabletted, the heavy 0.8-1.8g/ sheet of sheet.
Quality control index: calcium content is in calcium >=13.3g/100g.
The invention has the beneficial effects as follows: donkey-hide gelatin, calcium carbonate, isoflavones and extract from ants carry out reasonable compatibility and make beauty treatment replenishing the calcium dispersing tablet, donkey-hide gelatin carries out micronizing and is easy to dissolve and absorb, postmenopausal women is replenished the calcium, the improvement of anaemia (enrich blood, mend iron), beauty treatment people's constitution will play actively and advantageous effect, and carry taking convenience, effect stability.Beauty treatment is replenished the calcium the stable processing technique, reasonable, feasible of dispersing tablet, is suitable for suitability for industrialized production.
Detailed description of the invention:
Be illustrated further below in conjunction with detailed description of the invention.
Embodiment 1: donkey-hide gelatin first carries out micro mist process, then calcium carbonate, isoflavones and extract from ants are pulverized, and cross 60 mesh sieves, and the coarse granule that do not sieve should be pulverized, raw material for standby after sieving.Microcrystalline cellulose all crosses 60 mesh sieves, raw material for standby after sieving.The actual inventory of each raw material is calculated by formula ratio.Mixing 40 minutes by having taken each raw material, making evenly, to add ethanol (60%) softwood processed in right amount, crossing 24 mesh sieve wet granulars, obtained wet granular in an oven, 60 DEG C of dryings 3 hours.Cross the whole grain of 12 mesh sieve, add PVPP and dolomol mixes, obtain dry particle.By particle tabletted, the heavy 0.8g/ sheet of sheet.
Embodiment 2: donkey-hide gelatin first carries out micro mist process, then calcium carbonate, isoflavones and extract from ants should first be pulverized, and cross 60 mesh sieves, and the coarse granule that do not sieve should be pulverized, raw material for standby after sieving.Microcrystalline cellulose all crosses 80 mesh sieves, raw material for standby after sieving.The actual inventory of each raw material is calculated by formula ratio.Mixing 30 minutes by having taken each raw material, making evenly, to add ethanol (70%) softwood processed in right amount, crossing 12 mesh sieve wet granulars, obtained wet granular in an oven, 50 DEG C of dryings 4 hours.Cross the whole grain of 18 mesh sieve, add PVPP and dolomol mixes, obtain dry particle.By particle tabletted, the heavy 1.0g/ sheet of sheet.
Embodiment 3: donkey-hide gelatin first carries out micro mist process, then calcium carbonate, isoflavones and extract from ants should first be pulverized, and cross 120 mesh sieves, and the coarse granule that do not sieve should be pulverized, raw material for standby after sieving.Microcrystalline cellulose all crosses 100 mesh sieves, raw material for standby after sieving.The actual inventory of each raw material is calculated by formula ratio.Mixing 20 minutes by having taken each raw material, making evenly, to add ethanol (90%) softwood processed in right amount, crossing 20 mesh sieve wet granulars, obtained wet granular in an oven, 40 DEG C of dryings 5 hours.Cross the whole grain of 30 mesh sieve, add PVPP and dolomol mixes, obtain dry particle.By particle tabletted, the heavy 1.8g/ sheet of sheet.
To replenish the calcium the instructions of taking of sheet: one time 1, take 2 day.
To replenish the calcium the curative effect of sheet: this product has taken nearly hundred examples, through following up a case by regular visits to 66 examples, wherein 55 examples improved of calcium deficiency people's constitution, 40 examples that anaemia people's constitution improves, invalid 0 example.Analyze from above, sheet of replenishing the calcium can reach and will play actively and the object of advantageous effect the improvement of calcium deficiency, anaemia sugar people's constitution.
Last it is noted that obviously, above-described embodiment is only for example of the present invention is clearly described, and the restriction not to embodiment.For those of ordinary skill in the field, can also make other changes in different forms on the basis of the above description, thus the apparent change of extending out or variation be still among protection scope of the present invention.
Claims (12)
1. the production technology of formula for a product and production technology micro mist, pulverizing, granulation, drying, whole grain, total mixed, compressing tablet; Its feature is, first micro mist, pulverizes and sieves, and then calculates the actual inventory of each raw material by formula ratio.
2. micro mist, pulverize and sieve: it is for subsequent use that donkey-hide gelatin first should carry out micro mist raw materials treated; Calcium carbonate crosses 60-120 mesh sieve, raw material for standby after sieving; Isoflavones is pulverized, and crosses 60-120 mesh sieve, raw material for standby after sieving; Extract from ants is pulverized, and crosses 60-120 mesh sieve, raw material for standby after sieving; Microcrystalline cellulose crosses 60-120 mesh sieve, raw material for standby after sieving.
3. feed intake: the actual inventory calculating each raw material by formula ratio.
4. mixing and wet granular processed: will take each raw material mixing 10-50 minute, makes evenly, to add 40-90% appropriate amount of ethanol softwood, crosses 12-30 mesh sieve wet granular.
5. dry: obtained wet granular in an oven, 40 DEG C of-60 DEG C of dry 3-5 hour.
6. whole grain and total mixed: cross the whole grain of 12-30 mesh sieve, adds PVPP and dolomol mixes, and obtains dry particle.
7. compressing tablet: after semi-finished product detect, by particle tabletted, the heavy 0.8-1.8g/ sheet of sheet.
8. quality control index: tablet weight variation≤5%, calcium content (in calcium, g/100g) >=13.3.
9. concrete steps are as follows, as claimed in claim 1: this technical products formula is 500 parts, donkey-hide gelatin, 500 parts, calcium carbonate, isoflavones 250 parts, extract from ants 130 parts, microcrystalline cellulose 75 parts, PVPP 30 parts, dolomol 15 parts and appropriate amount of ethanol.
10. the present invention adopts the ethanol of debita spissitudo as adhesive, then dries, whole grain, adds magnesium stearate lubricant mixing, compressing tablet.
11. as claimed in claim 1: this technology production beauty treatment replenish the calcium dispersion blade raw material be donkey-hide gelatin, calcium carbonate, isoflavones, extract from ants and microcrystalline cellulose.
12. as claimed in claim 1: this technology adopts micro mist, pulverizes, sieves, granulates, drying, whole grain, always to mix and the production technology of compressing tablet: (1) micro mist, pulverize and sieve, donkey-hide gelatin should first carry out micro mist process, calcium carbonate, isoflavones and extract from ants and pulverize, and cross 60-120 mesh sieve, raw material for standby after sieving; (2) microcrystal cellulose powder crosses 60-120 mesh sieve, raw material for standby after sieving; (3) feed intake, calculate the actual inventory of each raw material by formula ratio; (4) mixing and wet granular processed: by having taken each raw material mixing 10-50 minute, making to mix, having added ethanol (40-90%) softwood processed in right amount, crosses 12-30 mesh sieve wet granular; (5) dry, obtained wet granular in an oven, 40 DEG C of-60 DEG C of dry 3-5 hour; (6) whole grain is with total mixed, and the whole grain of 12-30 mesh sieve excessively, adds PVPP and dolomol mixes, and obtains dry particle; (7) compressing tablet: after semi-finished product detect, by particle tabletted, the heavy 0.8-1.8g/ sheet of sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510347932.8A CN105410937A (en) | 2015-06-23 | 2015-06-23 | Production process of beatifying calcium dispersible tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510347932.8A CN105410937A (en) | 2015-06-23 | 2015-06-23 | Production process of beatifying calcium dispersible tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105410937A true CN105410937A (en) | 2016-03-23 |
Family
ID=55489855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510347932.8A Pending CN105410937A (en) | 2015-06-23 | 2015-06-23 | Production process of beatifying calcium dispersible tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105410937A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107897936A (en) * | 2018-01-15 | 2018-04-13 | 中鸿纳米纤维技术丹阳有限公司 | A kind of multifunctional full-nutritious pelelith nutrient |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628749A (en) * | 2004-10-20 | 2005-06-22 | 北京东方兴企食品工业技术有限公司 | Eatable ants and its preparation method |
| CN1651063A (en) * | 2004-12-22 | 2005-08-10 | 北京玉泉中医院 | Redy preparation Chinese medicine for treating kinetic fatigue and chronic fatigue syndrome |
| CN1709384A (en) * | 2005-06-22 | 2005-12-21 | 白新鹏 | Ovarium-nourishing capsule for regulating female incretion and its preparing method |
| CN101204400A (en) * | 2006-12-19 | 2008-06-25 | 冉淑芹 | Prescripton and preparing method of colla corii asini line products |
| CN102166227A (en) * | 2011-02-25 | 2011-08-31 | 郭景龙 | Pharmaceutical composition with function of enhancing immunity |
| CN102524638A (en) * | 2010-12-31 | 2012-07-04 | 武汉一元堂生物科技有限公司 | Health food formula applicable for ovary maintenance, endocrine modulation, anti-oxidation and senility delay of female and method for preparing health food formula |
| CN104491098A (en) * | 2015-01-19 | 2015-04-08 | 孙宁 | Instant donkey-hide gelatin product for patient with lung cancer and preparation method thereof |
-
2015
- 2015-06-23 CN CN201510347932.8A patent/CN105410937A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628749A (en) * | 2004-10-20 | 2005-06-22 | 北京东方兴企食品工业技术有限公司 | Eatable ants and its preparation method |
| CN1651063A (en) * | 2004-12-22 | 2005-08-10 | 北京玉泉中医院 | Redy preparation Chinese medicine for treating kinetic fatigue and chronic fatigue syndrome |
| CN1709384A (en) * | 2005-06-22 | 2005-12-21 | 白新鹏 | Ovarium-nourishing capsule for regulating female incretion and its preparing method |
| CN101204400A (en) * | 2006-12-19 | 2008-06-25 | 冉淑芹 | Prescripton and preparing method of colla corii asini line products |
| CN102524638A (en) * | 2010-12-31 | 2012-07-04 | 武汉一元堂生物科技有限公司 | Health food formula applicable for ovary maintenance, endocrine modulation, anti-oxidation and senility delay of female and method for preparing health food formula |
| CN102166227A (en) * | 2011-02-25 | 2011-08-31 | 郭景龙 | Pharmaceutical composition with function of enhancing immunity |
| CN104491098A (en) * | 2015-01-19 | 2015-04-08 | 孙宁 | Instant donkey-hide gelatin product for patient with lung cancer and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107897936A (en) * | 2018-01-15 | 2018-04-13 | 中鸿纳米纤维技术丹阳有限公司 | A kind of multifunctional full-nutritious pelelith nutrient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141709B (en) | Carp feed and preparation method thereof | |
| JP6435333B2 (en) | Composition for prevention and treatment of cancer-related fatigue comprising processed ginseng powder or processed ginseng extract with increased ginsenoside component | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| Zhang et al. | The haematopoietic effect of Panax japonicus on blood deficiency model mice | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN105146267A (en) | Composition with weight losing function and application thereof | |
| CN102047979A (en) | Phytosterol formula milk powder | |
| CN101658525B (en) | Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof | |
| CN102349608A (en) | Healthcare product combination for clearing and nourishing throat and preparation method thereof | |
| CN106036898A (en) | Composition having anti-fatigue effects and preparation method and use thereof | |
| JP2017149749A (en) | Pharmaceutical composition for preventing or treating sarcopenia, and health functional food composition for preventing or improving sarcopenia | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
| CN105410937A (en) | Production process of beatifying calcium dispersible tablet | |
| CN105380031A (en) | Health food and preparation method thereof | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| KR20140016863A (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| CN102132873A (en) | Medicine or health-care food for supplementing blood and regulating immunity | |
| KR101744061B1 (en) | Composition for improving diabetes and bloodstream and method for preparing the same | |
| CN101637268B (en) | Health-care food having functions of freckle elimination and radiation resistance and preparation method thereof | |
| CN108420890A (en) | A kind of composition and preparation method thereof with effect for reducing blood fat | |
| CN105360798B (en) | A kind of enhancing endurance and the maca prescription of explosive force and preparation method thereof | |
| CN106177227A (en) | A kind of compositions containing coenzyme Q10 strengthening body immunity | |
| CN112674332A (en) | Antioxidant composition containing folic acid and nutrition tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160323 |
|
| WD01 | Invention patent application deemed withdrawn after publication |